CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)

Yunhong Tian†,
Jianlin Wu†,
Cristian Chagas,
Yichao Du,
Huan Lyu,
Yunhong He,
Shouliang Qi,
Yong PengEmail author and
Jiani HuEmail author

†Contributed equally

BMC Cancer201818:1187

https://doi.org/10.1186/s12885-018-5072-4

Received: 23 August 2018
Accepted: 9 November 2018
Published: 29 November 2018

Open Peer Review reports

Abstract

Background

Accurate and early prognosis of disease is essential to clinical decision making, particularly in diseases, such as HCC, that are typically diagnosed at a late stage in the course of disease and therefore carry a poor prognosis. CDCA5 is a cell cycle regulatory protein that has shown prognostic value in several cancers.

Methods

We retrospectively evaluated 178 patients with HCC treated with curative liver resection between September 2009 and September 2012 at Nanchong Central Hospital in Nanchong, Sichuan Province, China. Patients were screened for their CDCA5 expression levels and assigned to either the high or low expression group. Patient demographics, comorbidities, clinicopathologic data, such as tumor microvascular invasion status and size, and long-term outcomes were compared between the two groups. The effect of CDCA5 on the proliferation of liver cancer cells was analyzed using in vitro and in vivo assays.

Results

The present study found that increased CDCA5 expression was associated with increased tumor diameter and microvascular invasion in HCC. It was also found that CDCA5 overexpression may be associated with liver cancer cells. Additionally, this study confirmed that CDCA5 expression was increased in HCC tissue versus normal liver tissue, that CDCA5 expression was associated with decreased survival and that CDCA5 knockdown using shRNA led to cell cycle arrest in the G2/M phase.